- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02400827
Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors (OVAMAR)
Study About Contamination of Ovarian Tissue by RT-PCR in Children With Solid Tumors.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Some solid tumors have high risk of metastatic localization including in ovaries. There is concern over the possible presence of malignant cells in ovarian tissue that could cause a recurrence of the primary disease after reimplantation. Thus, the possibility of ovarian tissue involvement needs to be evaluated with sensitive molecular methods. Those techniques are now available for leukaemia but histology is still the only way for solid tumors.
Based on our experience in detection by RT-PCR of minimal residual disease (MRD) in neuroblastoma since 1994 [Tchirkov et al. 2003] and in ovarian tissue cryopreservation since 1995 [Schubert et al. 2005, Chambon in press], we want to develop a specific and sensitive method for residual disease detection by RT-PCR in order to evaluate the tumor contamination of ovarian harvested tissue.
Study population: We chose 3 models of pediatric solid tumors with high risk of metastases and which often require sterilizing treatments (chemo and/or radiotherapy): neuroblastoma, Ewing tumor and alveolar rhabdosarcoma. We will use four tumor cells lines: IMR32 and SK-NSH for neuroblastoma; RD-ES for Ewing tumor; RH-30 for rhabdosarcoma. We plan to use 20 fragments per line.
Study duration: 12 months Study design: Ovarian tissue without known malignancy but with a condition warranting laparoscopy (benign cysts) will be harvested during kystectomy (perikystic tissue).
The harvested ovarian cortex will be cut: one half will be frozen according to our routine protocol [Schubert et al. 2005] and the other half will be contaminated with tumor cells lines. Then, detection of the specific transcript will be done by RT-PCR in fresh tissue and after freeze/thaw. Total RNA will be extracted with the TRI-reagent and qRT-PCR will be performed using the "TaqMan" technology.
Primary endpoint: to reach a sensitivity about 1/106 cells.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
-
Clermont-Ferrand, Frankrig, 63003
- Rekruttering
- CHU de Clermont-Ferrand
-
Ledende efterforsker:
- Justyna KANOLD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Women of any age, diagnosed with a benign cyst that needs a laparoscopy may be included
Exclusion Criteria:
-
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
cryopreservation
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
malignant cells about 1/10*6 cells.
Tidsramme: at day 1
|
at day 1
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Justyna KANOLD, University Hospital, Clermont-Ferrand
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CHU-0229
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Minimal resterende sygdom
-
Xianmin Song, MDRekruttering
-
AmgenAfsluttetMyelodysplastisk syndrom | Tilbagefaldende/Refraktær AML | Minimal Residual Disease Positiv AMLForenede Stater, Canada, Tyskland, Holland
-
University of LeicesterAktiv, ikke rekrutterendeKræftDet Forenede Kongerige
-
Guangdong Provincial People's HospitalShenzhen Chipscreen Biosciences Co.LtdRekrutteringMinimal resterende sygdom | AML, voksenKina
-
Tongji HospitalIkke rekrutterer endnuTilbagevenden | HCC | Minimal resterende sygdomKina
-
Karolinska University HospitalMedical University of Graz; Aarhus University Hospital; Centre Hospitalier... og andre samarbejdspartnereTilmelding efter invitationAdenocarcinom i bugspytkirtlenSverige
-
University Hospital, Clermont-FerrandUkendtMinimal resterende sygdom | Bevarelse af fertilitetFrankrig
-
Centre Hospitalier Universitaire de BesanconUniversity Hospital, Rouen; CHU de Reims; Central Hospital, Nancy, France; University... og andre samarbejdspartnereAfsluttetNeoplastisk patologi | Autokonserveret ovarievævFrankrig
-
Institute of Hematology & Blood Diseases HospitalIkke rekrutterer endnuMinimal resterende sygdom | Knoglemarvstransplantation | Ph+ ALLEKina
-
Caris Science, Inc.RekrutteringKræft | Minimal resterende sygdom | Tidlig opdagelse af kræftForenede Stater
Kliniske forsøg med ondartede celler
-
Shanghai Ming Ju Biotechnology Co., Ltd.RekrutteringSystemisk lupus erythematosusKina
-
Liangjing LuShanghai Ming Ju Biotechnology Co., Ltd.Rekruttering
-
Ruijin HospitalRekruttering
-
Ruijin HospitalRekrutteringRecidiverende eller refraktært B-celle lymfomKina
-
TruDiagnosticSRWRekruttering
-
Kamau TherapeuticsRekrutteringSeglcellesygdomForenede Stater
-
Weill Medical College of Cornell UniversityAngiocrine BioscienceRekruttering
-
Lyell Immunopharma, Inc.RekrutteringLymfom, B-celle | Diffust storcellet B-celle lymfom refraktær | Non-Hodgkin lymfom | Refraktær non-Hodgkin lymfom | Stort B-celle lymfom | Diffust storcellet B-celle lymfom tilbagefald | Recidiverende non-Hodgkin lymfom | Diffust storcellet B-celle lymfom (DLBCL) | Non-Hodgkin lymfom refraktært/tilbagefaldendeForenede Stater
-
Autolus LimitedRekrutteringProgressiv multipel skleroseSpanien, Det Forenede Kongerige, Forenede Stater
-
Abeona Therapeutics, IncTilmelding efter invitation